Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …

Summary Background The omicron (B. 1.1. 529) variant of SARS-CoV-2 is highly
transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due …

Outcome of early treatment of COVID‐19 with antivirals or anti‐spike monoclonal antibodies
(MABs) in patients with haematological malignancies (HM) is unknown. A retrospective …

Background Due to potentially immune-escaping virus variants and waning immunity, a third
SARS-CoV-2 vaccination dose is increasingly recommended. However, data in patients with …

Patients with cancer are at high risk for severe clinical courses of COVID-19 and delays of
antineoplastic treatment due to SARS-CoV-2 infections (Pinato et al., 2022). SARS-CoV-2 …

Abstract Background Although SARS-CoV-2 vaccines immunogenicity in patients with
cancer has been investigated, whether they can significantly improve the severity of COVID …

Background COVID-19 sequelae can affect about 15% of patients with cancer who survive
the acute phase of SARS-CoV-2 infection and can substantially impair their survival and …

Importance Accurate identification of patient groups with the lowest level of protection
following COVID-19 vaccination is important to better target resources and interventions for …